In the sensitivity analysis applying the weighted median method, the association of genetically proxied PCSK9 inhibition with prostate cancer (OR: 0.85; 95% CI 0.76–0.95; P = 0.005; Additional file 1: Table S6) remained significant. This evidence concerns the gene PCSK9 and prostate carcinoma.